Spontaneous Epithelial-Mesenchymal Transition and Resistance to HER-2-Targeted Therapies in HER-2-Positive Luminal Breast Cancer

Resistance to trastuzumab, a rationally designed HER-2-targeting antibody, remains a major hurdle in the management of HER-2-positive breast cancer. Preclinical studies suggest the mechanisms of trastuzumab resistance are numerous. Unfortunately, the majority of these studies are based around HER-2-...

Descripción completa

Detalles Bibliográficos
Autores principales: Lesniak, David, Sabri, Siham, Xu, Yaoxian, Graham, Kathryn, Bhatnagar, Pravin, Suresh, Mavanur, Abdulkarim, Bassam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753362/
https://www.ncbi.nlm.nih.gov/pubmed/23991019
http://dx.doi.org/10.1371/journal.pone.0071987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753362/
https://www.ncbi.nlm.nih.gov/pubmed/23991019
http://dx.doi.org/10.1371/journal.pone.0071987

Ejemplares similares